Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Mipomersen (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS-FH
- Sponsors Kastle Therapeutics
- 15 Jun 2016 Status changed from active, no longer recruiting to completed.
- 06 May 2016 The trial has been completed in Spain (end date:2016-03-15), according to the European Clinical Trials Database.
- 22 Apr 2016 The trial has been completed in Sweden, Belgium, Hungary, Germany, Czech Republic, Greece, Italy, Poland, Slovakia, Netherlands and Denmark (end date:2016-02-15).